

IN THE CLAIMS:


Please amend the claims as follows:

1. (Currently amended) A method for examining colorectal cancer and colorectal adenoma comprising:

a) providing a patient in need of screening for colorectal cancer or adenoma; and
b) assaying the binding of an antibody to an antigen in tissues, body fluid or feces—of patients, or extracts thereof, of the patient wherein said antigen is present in cells expressing HEC-GlcNAc6ST gene encoding GlcNAc-6-sulfotransferase and is absent in cells expressing GlcNAc6ST-1 or I-GlcNAc6ST gene.

2. (Previously presented) The method of claim 1, wherein said antigen is present in cells transduced with HEC-GlcNAc6ST gene and is absent in cells transduced with GlcNAc6ST-1 gene or I-GlcNAc6ST gene.

3. (Previously presented) The method of claim 1, wherein said antigen comprises the sugar residues expressed by the following formula:



where, R1 represents sugar residues added by other enzymes and is not limited in structure; Gal β represents β galactose, GlcNAc β represents β N-acetylglucosamine, Gal $\beta 1-3/4$ represents binding of 1 position of Gal β and 3 position and/or 4 position of GlcNAc β , (SO₃-6) represents addition of a sulfate group to 6 position of GlcNAc β , R2 represents -3GalNAc α , -3Gal β or -2Man α and binds to 1 position of GlcNAc β .

4. (Previously presented) The method according to claim 1, wherein said antibody is MECA-79 antibody (Pharmingen, catalog No. 09961D).

Serial No.: 10/568,544

5. (Currently amended) A method for examining colorectal cancer and colorectal adenoma comprising:


- a) providing a patient in need of screening for colorectal cancer or adenoma; and
- b) assaying the binding of MECA-79 antibody or another antibody having the same binding specificity with tissues, body fluid, feces, or extract thereof of test subjects~~the patient~~.

6. (Previously presented) The method according to claim 5 comprising binding a labeled probe to said antibody and assaying the label qualitatively or quantitatively.

7. (Withdrawn) An examination reagent for colorectal cancer and colorectal adenoma comprising, as a major component, an antibody (including MECA-79 antibody) reacting specifically with an antigen carrying sugar residues, which is present in cells expressing HEC-GlcNAc6ST gene and is absent or almost absent in cells expressing GlcNAc6ST-1 or GlcNAc6ST gene.

8. (Withdrawn) An examination reagent for colorectal cancer and colorectal adenoma comprising, as a major component, an antibody (including MECA-79 antibody) reacting specifically with an antigen carrying sugar residues, which is present in cells transduced with HEC-GlcNAc6ST gene and is absent or almost absent in cells transduced with GlcNAc6ST-1 or GlcNAc6ST gene.

9. (Withdrawn) An examination reagent for colorectal cancer and colorectal adenoma comprising, as a major component, an antibody (including MECA-79 antibody) reacting specifically with an antigen carrying sugar residues, which are present in tissues, body fluid or feces of patients with colorectal cancer and colorectal adenoma and expressed by the following general formula:



Serial No.: 10/568,544

where, R1 represents sugar residues added by other enzymes and is not limited in structure; Gal β represents β galactose, GlcNAc β represents β N-acetylglucosamine, Gal β 1-3/4 represents binding of 1 position of Gal β and 3 position and/or 4 position of GlcNAc β , (SO₃-6) represents addition of a sulfate group to 6 position of GlcNAc β , R2 represents -3GalNAc α , -3Gal β or -2Man α and binds to 1 position of GlcNAc β .

10. (Withdrawn) An examination reagent for colorectal cancer and colorectal adenoma comprising MECA-79 antibody as a major component.

11. (New) The method of claim 1 wherein the binding of the antibody is performed in feces or extracts thereof.

12. (New) The method of claim 5 wherein the binding of the antibody is performed in feces or extracts thereof.

13. (New) The method of claim 1 wherein the binding of the antibody is performed in body fluid or extracts thereof.

14. (New) The method of claim 5 wherein the binding of the antibody is performed in body fluid or extracts thereof.